• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec3
HSBC Increased Holdings in Bausch Health Companies
09:22
Nov21
Eagle Health Investments LP reduces holdings in Bausch Health Companies Inc.
09:49
Nov9
Campbell & CO Increases Holdings in BioMarin Pharmaceutical Inc.
09:34
Nov4
BioMarin Pharmaceuticals Receives FDA Priority Review for PALYNZIQ® Treatment Expansion
01:37
Nov2
Wall Street Zen downgrades BMRN's rating to hold from buy
05:12
Nov1
Morgan Stanley Maintains Buy Rating on BioMarin Pharmaceutical
03:52

Schedules & Filings

Schedules
Filings
Oct27
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 776.13 M, Net Income -30.74 M, EPS -0.16

BioMarin Pharmaceutical Inc. (BMRN.US) Q3 2025 Earnings Conference CallBioMarin Pharmaceutical Inc. (BMRN.US) Q3 2025 Earnings Conference Call
Aug4
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 825.41 M, Net Income 240.53 M, EPS 1.2297

BioMarin Pharmaceutical Inc. (BMRN.US) Q2 2025 Earnings Conference CallBioMarin Pharmaceutical Inc. (BMRN.US) Q2 2025 Earnings Conference Call
May1
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 745.15 M, Net Income 185.69 M, EPS 0.9544

BioMarin Pharmaceutical Inc. (BMRN.US) Q1 2025 Earnings Conference CallBioMarin Pharmaceutical Inc. (BMRN.US) Q1 2025 Earnings Conference Call
View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More